Skip to main content

Table 1 Summary of the results of test accuracy in studies comparing whole-body MRI with FDG-PET/CT in the detection of sites of tumour recurrence within lymph nodes

From: Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology

Study

Population & setting

Reference standard

Outcome [95 % CI]

PET-CT

WB-MRI

Sensitivity

PPV

Sensitivity

PPV

Pfannenberg et al. (2007) [15]

Recurrent melanoma

Histology or 8 months follow-up

85 [77–91] %

94 % [87–97] %

66 [56–74] %

84 % [74–90] %

Self-controlled study (n = 64)

Schmidt et al. (2009) [16]

Recurrent Colorectal Cancer

Follow-up (mean 11 months)

93 [78–98] %

100 [86–100] %

62 [44–77] %

82 [61–93] %

Self-controlled study (n = 24)

Ng et al. (2010) [18]

Recurrent Head & Neck Cancer

Histology or 12 months follow-up

80 [61–91] %

77 [58–89] %

88 [70–96] %

81 [63–92] %

Self-controlled study (n = 179)

Laurent et al. (2010) [19]

Recurrent melanoma

Histology or 6 months follow-up

83 [65–92] %

100 [86–100] %

90 [74–96] %

96 [82–99] %

Self-controlled study (n = 35)

Jouvet et al. (2014) [20]

Recurrent melanoma

Histology or ≥6 months follow-up

96 [79–99] %

96 [79–99] %

87 [68–95] %

100 [84–100] %

Self-controlled study (n = 37)

Weighted averages

(n = 339)

 

87 [81–91] %

93 [89–96] %

74 [67–79] %

87 [81–91] %